Tenomix is a medical technology startup founded in 2021, based in London, Canada. It focuses on developing innovative solutions for cancer screening and pathology diagnostics. The company was established by Saumik Biswas, Eveline Pasman, Michael Lavdas, and Sherif Abdou, all alumni of the Medical Innovation Fellowship program at Western University. Known for its pioneering device, the "Lymphonator," Tenomix has successfully secured funding of $2.1 million in 2024, indicating strong investor confidence in its mission to revolutionize cancer staging, particularly for colorectal cancer.
Attribute | Information |
---|---|
Founding Date | 2021 |
Headquarters | London, Canada |
Founders | Saumik Biswas, Eveline Pasman, Michael Lavdas, Sherif Abdou |
Revenue | Not disclosed |
Profits | Not disclosed |
Key Investors | OBIO, FACIT, Phoenix Fire Fund, Ontario Centre of Innovation's Life Science Innovation Fund |
Industry | Medical Technology |
Number of Employees | Not disclosed |
Tenomix was founded in 2021 when four entrepreneurs identified significant inefficiencies in the pathology process related to cancer staging. This led to the development of the "Lymphonator," a device aimed at automating the labor-intensive and often imprecise manual search for lymph nodes conducted by pathologists. Within the first ten months, the company developed its initial prototype, began testing on animal and human tissues, and secured over $490,000 in non-dilutive funding, setting the foundation for further innovation and development.
Tenomix operates primarily in the field of medical devices, focusing on automation and AI-driven solutions to enhance accuracy and efficiency in pathology. Their main product, the "Lymphonator," integrates robotics, ultrasound imaging, and artificial intelligence to systematically identify lymph nodes during cancer tissue examination. Highlights in its development timeline include:
Currently, Tenomix is engaged in validating its technology across hospitals in Canada and the U.S. The company is positioning itself as a leader in the pathology tech space, capitalizing on the demand for automation in laboratory processes. The "Lymphonator" is set to address the challenges of traditional cancer staging methods by offering a more reliable and efficient alternative, thus reinforcing its market presence as it seeks to gain regulatory approvals for broader market engagement.
Tenomix's innovative approach in addressing long-standing inefficiencies in pathology workflows underscores its significance in the medical device industry. By leveraging cutting-edge technologies, the company is well-positioned to potentially transform cancer treatment paradigms, particularly with its focus on colorectal cancer staging. Looking ahead, Tenomix aims to expand its technological scope and presence in the healthcare market, driven by its robust foundational accomplishments and recent investment influxes, paving the way for future growth and impact on global healthcare practices.